Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $50.02 million. The enterprise value is $40.28 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 27.79 million shares outstanding. The number of shares has increased by 75.86% in one year.
| Current Share Class | 27.79M |
| Shares Outstanding | 27.79M |
| Shares Change (YoY) | +75.86% |
| Shares Change (QoQ) | +4.42% |
| Owned by Insiders (%) | 4.68% |
| Owned by Institutions (%) | 7.15% |
| Float | 26.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 420.33 |
| PB Ratio | 6.65 |
| P/TBV Ratio | 6.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.97 |
| Quick Ratio | 2.85 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -204.95% and return on invested capital (ROIC) is -117.83%.
| Return on Equity (ROE) | -204.95% |
| Return on Assets (ROA) | -82.80% |
| Return on Invested Capital (ROIC) | -117.83% |
| Return on Capital Employed (ROCE) | -247.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$816,448 |
| Employee Count | 25 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $536,815 in taxes.
| Income Tax | 536,815 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.35% in the last 52 weeks. The beta is 0.19, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -43.35% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 46.14 |
| Average Volume (20 Days) | 262,792 |
Short Selling Information
The latest short interest is 302,677, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 302,677 |
| Short Previous Month | 326,688 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.14% |
| Short Ratio (days to cover) | 1.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | -10.65M |
| Operating Income | -20.36M |
| Pretax Income | -21.54M |
| Net Income | -20.41M |
| EBITDA | -20.32M |
| EBIT | -20.36M |
| Earnings Per Share (EPS) | -$0.89 |
Full Income StatementBalance Sheet
The company has $10.39 million in cash and $653,015 in debt, giving a net cash position of $9.73 million or $0.35 per share.
| Cash & Cash Equivalents | 10.39M |
| Total Debt | 653,015 |
| Net Cash | 9.73M |
| Net Cash Per Share | $0.35 |
| Equity (Book Value) | 7.34M |
| Book Value Per Share | 0.27 |
| Working Capital | 7.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.87 million and capital expenditures -$22,493, giving a free cash flow of -$18.90 million.
| Operating Cash Flow | -18.87M |
| Capital Expenditures | -22,493 |
| Free Cash Flow | -18.90M |
| FCF Per Share | -$0.68 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |